SCHEMBL17727

SCHEMBL17727

CC1(C)NCCNC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1629714 0.97
Bicarbonate SCHEMBL5274811 0.87
Bicarbonate SCHEMBL5274805 0.87
Bicarbonate SCHEMBL5274802 0.85
SCHEMBL6061483 0.82
Tert-Butyl Formate SCHEMBL28805266 0.80 TDP1 (0.43)
SCHEMBL19887993 0.75
SCHEMBL10840913 0.72 CYP19A1 (0.33)
SCHEMBL3543029 0.72 TSHR (0.38)
SCHEMBL5244811 0.70 ALDH1A1 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4532496-A1 NOVEL PAR-2 INHIBITORS Domain Therapeutics (FR) 2025-04-09 EP claimed
US-20240066027-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2024-02-29 US claimed
WO-2023233033-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2023-12-07 WO claimed
EP-4255904-A2 NOVEL PAR-2 INHIBITORS Domain Therapeutics (FR) 2023-10-11 EP claimed
WO-2022117882-A2 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2022-06-09 WO claimed
WO-2022046682-A1 BROMODOMAIN AND EXTRA TERMINAL DOMAIN (BET) INHIBITOR COMPOSITIONS AND METHODS THEREOF FOR USE AS ANTI-AGING AGENTS MDI BIOLOGICAL LABORATORY (US) 2022-03-03 WO claimed
EP-3209664-A1 BICYCLIC HETEROARYL AMINE COMPOUNDS AS PI3K INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-30 EP claimed
US-12636290-B2 BET inhibitors for modulating DUX4 expression in FSHD SAINT LOUIS UNIVERSITY (US) 2026-05-26 US disclosed
US-20260008783-A1 MODULATORS OF FSHR AND USES THEREOF GEDEON RICHTER PLC (HU) 2026-01-08 US disclosed
US-20250320224-A1 NOVEL PAR-2 INHIBITORS DOMAIN THERAPEUTICS (FR) 2025-10-16 US disclosed
US-20250320213-A1 Nitrogen-Containing Heterocyclic Compounds PFIZER INC. (US) 2025-10-16 US disclosed
EP-4577206-A2 NOVEL MODULATORS OF FSHR AND USES THEREOF Celmatix Inc. (US) 2025-07-02 EP disclosed
US-20250136581-A1 SUBSTITUTED TRIAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) 2025-05-01 US disclosed
US-4167512-A Synthesis of 2-keto-1,4-diazacycloalkanes THE B. F. GOODRICH COMPANY (US) 1979-09-11 US disclosed
EP-0001559-A2 Synthesis of 2-keto-1,4-diazacycloalkanes The B.F. GOODRICH Company (US) 1979-05-02 EP disclosed
EP-0001284-A1 UV-light stabilized compositions containing substituted 2-keto-1,4-diazacycloalkanes The B.F. GOODRICH Company (US) 1979-04-04 EP disclosed
US-4058462-A System for sustained release of phenolic material from porous granules of insoluble polymeric phenolic complexes GAF CORPORATION (US) 1977-11-15 US disclosed
US-3985540-A Metal complexes of hydroxyquinoline and polymeric porous granules GAF CORPORATION (US) 1976-10-12 US disclosed
US-3970606-A N-vinyl lactam interpolymers useful as thickening agents GAF CORPORATION (US) 1976-07-20 US disclosed
US-3954682-A GRANULES OR BEADS GAF CORPORATION (US) 1976-05-04 US disclosed